Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials A Lin, CJ Giuliano, A Palladino, KM John, C Abramowicz, ML Yuan, ... Science translational medicine 11 (509), eaaw8412, 2019 | 549 | 2019 |
Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract JC Smith, EL Sausville, V Girish, ML Yuan, A Vasudevan, KM John, ... Developmental cell 53 (5), 514-529. e3, 2020 | 517* | 2020 |
Elite male faculty in the life sciences employ fewer women JM Sheltzer, JC Smith Proceedings of the National Academy of Sciences 111 (28), 10107-10112, 2014 | 488 | 2014 |
Aneuploidy drives genomic instability in yeast JM Sheltzer, HM Blank, SJ Pfau, Y Tange, BM George, TJ Humpton, ... Science 333 (6045), 1026-1030, 2011 | 447 | 2011 |
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity M Hoffmann, H Hofmann-Winkler, JC Smith, N Krüger, P Arora, ... EBioMedicine 65, 2021 | 317 | 2021 |
Transcriptional consequences of aneuploidy JM Sheltzer, EM Torres, MJ Dunham, A Amon Proceedings of the National Academy of Sciences 109 (31), 12644-12649, 2012 | 285 | 2012 |
The aneuploidy paradox: costs and benefits of an incorrect karyotype JM Sheltzer, A Amon Trends in Genetics 27 (11), 446-453, 2011 | 274 | 2011 |
Single-chromosome gains commonly function as tumor suppressors JM Sheltzer, JH Ko, JM Replogle, NCH Burgos, ES Chung, CM Meehl, ... Cancer cell 31 (2), 240-255, 2017 | 217 | 2017 |
Systematic identification of mutations and copy number alterations associated with cancer patient prognosis JC Smith, JM Sheltzer Elife 7, e39217, 2018 | 138 | 2018 |
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials A Lin, CJ Giuliano, NM Sayles, JM Sheltzer Elife 6, e24179, 2017 | 137 | 2017 |
Generating Single Cell–Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9 CJ Giuliano, A Lin, V Girish, JM Sheltzer Current Protocols in Molecular Biology 128 (e100), 2019 | 128 | 2019 |
Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies DA Lukow, EL Sausville, P Suri, NK Chunduri, A Wieland, J Leu, JC Smith, ... Developmental cell 56 (17), 2427-2439. e4, 2021 | 125 | 2021 |
Aneuploidy as a promoter and suppressor of malignant growth A Vasudevan, KM Schukken, EL Sausville, V Girish, OA Adebambo, ... Nature Reviews Cancer, 1-15, 2021 | 124 | 2021 |
A transcriptional and metabolic signature of primary aneuploidy is present in chromosomally unstable cancer cells and informs clinical prognosis JM Sheltzer Cancer research 73 (21), 6401-6412, 2013 | 104 | 2013 |
MELK expression correlates with tumor mitotic activity but is not required for cancer growth CJ Giuliano, A Lin, JC Smith, AC Palladino, JM Sheltzer Elife 7, e32838, 2018 | 86 | 2018 |
Increasing gender diversity in the STEM research workforce CW Greider, JM Sheltzer, NC Cantalupo, WB Copeland, N Dasgupta, ... Science 366 (6466), 692-695, 2019 | 85 | 2019 |
Single-chromosomal gains can function as metastasis suppressors and promoters in colon cancer A Vasudevan, PS Baruah, JC Smith, Z Wang, NM Sayles, P Andrews, ... Developmental Cell 52 (4), 413-428. e6, 2020 | 81 | 2020 |
Micronuclei-based model system reveals functional consequences of chromothripsis in human cells M Kneissig, K Keuper, MS de Pagter, MJ van Roosmalen, J Martin, H Otto, ... Elife 8, e50292, 2019 | 77 | 2019 |
Genome-wide identification and analysis of prognostic features in human cancers JC Smith, JM Sheltzer Cell reports 38 (13), 2022 | 68 | 2022 |
Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division JM Replogle, W Zhou, AE Amaro, JM McFarland, M Villalobos-Ortiz, ... Proceedings of the National Academy of Sciences 117 (48), 30566-30576, 2020 | 59 | 2020 |